Arrowhead Pharmaceuticals Inc. (ARWR)

32.12
NASDAQ : Health Technology
Prev Close 34.50
Day Low/High 31.80 / 34.93
52 Wk Low/High 10.41 / 35.41
Avg Volume 1.83M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 3.29B
EPS -0.70
P/E Ratio 75.00
Div & Yield N.A. (N.A)
Arrowhead Creates Hepatitis B Clinical Advisory Board And Names Dr. Robert Gish Chairman

Arrowhead Creates Hepatitis B Clinical Advisory Board And Names Dr. Robert Gish Chairman

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, announced today that prominent hepatologist Robert G.

Arrowhead Research To Present At BIO-Europe 2012

Arrowhead Research To Present At BIO-Europe 2012

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that Dr.

5 Stocks Under $10 Set to Trade Higher in November

5 Stocks Under $10 Set to Trade Higher in November

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Arrowhead Presents Data Showing 99% Target Knockdown In Monkeys Without Toxicity Using Subcutaneous Formulation Of Dynamic Polyconjugate SiRNA Delivery System

Arrowhead Presents Data Showing 99% Target Knockdown In Monkeys Without Toxicity Using Subcutaneous Formulation Of Dynamic Polyconjugate SiRNA Delivery System

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, announced that David Lewis, Ph.

Arrowhead Research Receives Notice Of Patent Allowance For New Formulation Of DPC SiRNA Delivery System Showing 500-Fold Increase In Potency

Arrowhead Research Receives Notice Of Patent Allowance For New Formulation Of DPC SiRNA Delivery System Showing 500-Fold Increase In Potency

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.

Arrowhead To Present At Rodman And Renshaw Annual Global Investment Conference

Arrowhead To Present At Rodman And Renshaw Annual Global Investment Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.

Arrowhead Completes Enrollment In Phase 1b Trial Of RNAi Drug Candidate CALAA-01

Arrowhead Completes Enrollment In Phase 1b Trial Of RNAi Drug Candidate CALAA-01

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of ...

Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead's Management Presents at 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead Enters Into Antibody Candidate Evaluation Agreement With Merck

Arrowhead Enters Into Antibody Candidate Evaluation Agreement With Merck

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it entered into an agreement with Merck, through a subsidiary, to undertake an evaluation of a novel proprietary ...

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 third quarter ended June 30, 2012.

Arrowhead Raises $6.2 Million Through Registered Direct Offering Of Common Stock And Warrants

Arrowhead Raises $6.2 Million Through Registered Direct Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has entered into a securities purchase agreement with institutional and individual investors to raise gross proceeds of approximately $6.

Arrowhead Research To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference

Arrowhead Research To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.

Arrowhead To Report Fiscal 2012 Third Quarter Financial Results

Arrowhead To Report Fiscal 2012 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 third quarter ended June 30, 2012, on Monday, August 13, 2012 at 4:30 p.

Arrowhead Announces Dosing Of First Patient With Anti-Obesity Treatment Adipotide® In A Phase 1 Clinical Trial

Arrowhead Announces Dosing Of First Patient With Anti-Obesity Treatment Adipotide® In A Phase 1 Clinical Trial

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide®, a new class of treatment for ...

Arrowhead Announces New Study Demonstrating Rapid Improvement In Pro-Diabetic Metabolic Markers With Anti-Obesity Drug Candidate, Adipotide®

Arrowhead Announces New Study Demonstrating Rapid Improvement In Pro-Diabetic Metabolic Markers With Anti-Obesity Drug Candidate, Adipotide®

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes ...

Arrowhead Research Advances ARC-520 Into IND-Enabling Studies For The Treatment Of Hepatitis B And Provides Guidance On Development Timeline

Arrowhead Research Advances ARC-520 Into IND-Enabling Studies For The Treatment Of Hepatitis B And Provides Guidance On Development Timeline

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical ...

Arrowhead Presents Data On DPC System At TIDES 2012

Arrowhead Presents Data On DPC System At TIDES 2012

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.

Arrowhead Reports Fiscal 2012 Second Quarter Financial Results

Arrowhead Reports Fiscal 2012 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March 31,...

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides

Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced that it has acquired Alvos Therapeutics, Inc.

Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment

Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed...

Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics

Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the...

Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011.

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity,...

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug...

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30,...

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S.

TheStreet Quant Rating: C+ (Hold)